1. Home
  2. Knowledge Base
  3. References
  4. Dual targeting NG2 and GD3A using Mab-Zap immunotoxin results in reduced glioma cell viability in vitro.

Dual targeting NG2 and GD3A using Mab-Zap immunotoxin results in reduced glioma cell viability in vitro.

Higgins S, Fillmore H, Ashkan K, Butt A, Pilkington G (2015) Dual targeting NG2 and GD3A using Mab-Zap immunotoxin results in reduced glioma cell viability in vitro. Anticancer Res 35:77-84.

Summary: Human glioma-derived cell lines were sequentially incubated with anti-NG2 and anti-GD3A coupled to Mab-ZAP (Cat. #IT-04) at 1 μg/ml and 5 μg/ml for 72 hours each. The combination therapy was significantly more effective than single therapy in eliminating the glioma cells.

Related Products: Mab-ZAP (Cat. #IT-04)